Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Trimmed by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. cut its stake in Centessa Pharmaceuticals by 48.7%, reducing their ownership to approximately 1.32% of the company, valued at $25 million.
• Other institutional investors, such as Janus Henderson Group PLC and Point72 Asset Management, increased their stakes significantly during the same period, indicating varying investor sentiment towards Centessa Pharmaceuticals.
• Centessa Pharmaceuticals recently reported earnings of ($0.38) per share, missing estimates, while analysts forecast a consensus rating of "Buy" with an average price target of $28.10.

T. Rowe Price Investment Management Inc. lessened its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 48.7% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,753,248 shares of the company's stock after selling 1,665,352 shares during the quarter. T. Rowe Price Investment Management Inc. owned 1.32% of Centessa Pharmaceuticals worth $25,212,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of CNTA. Janus Henderson Group PLC grew its position in Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after acquiring an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth approximately $20,994,000. Point72 Asset Management L.P. lifted its stake in Centessa Pharmaceuticals by 26.2% during the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock worth $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after purchasing an additional 685,371 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 24.3% during the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock worth $58,603,000 after purchasing an additional 684,391 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a research note on Friday. They issued an "outperform" rating and a $40.00 target price on the stock. Truist Financial assumed coverage on Centessa Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $30.00 target price on the stock. Chardan Capital reiterated a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Finally, Needham & Company LLC started coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $31.50.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 8,322 shares of the business's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total value of $126,744.06. Following the sale, the insider directly owned 208,163 shares in the company, valued at approximately $3,170,322.49. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the completion of the sale, the chief executive officer owned 221,017 shares in the company, valued at approximately $3,518,590.64. This trade represents a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock valued at $2,472,814 in the last ninety days. 7.09% of the stock is owned by insiders.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded down $0.07 during midday trading on Friday, hitting $16.49. The company's stock had a trading volume of 83,547 shares, compared to its average volume of 957,837. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average price is $15.61 and its 200-day moving average price is $14.49. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.60 and a 12 month high of $19.09. The company has a market capitalization of $2.21 billion, a PE ratio of -9.20 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.